Insmed Rattles Investors Despite Positive Phase III Data
By Staff Reports
Monday, July 1, 2013
Investors were less than impressed with the results from Insmed Inc.'s Phase III trial for Arikace, its liposomal amikacin for inhalation. The Monmouth Junction, N.J.-based company saw its shares (NASDAQ:INSM) plummet 18.7 percent, or $2.24, to close at $9.72 Monday.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.